J&J’s posdinemab data sharpen questions around tau biomarkers in Alzheimer’s

Although Johnson & Johnson discontinued posdinemab last year after its Phase II AuΤonomy study in Alzheimer’s disease missed its clinical and functional endpoints, data presented over the weekend at AD/PD still offer a useful lesson for the field: reducing a soluble tau biomarker is not the same as altering the tissue-level pathology that matters most for disease progression.

The study’s clinical endpoint data were clear: Posdinemab does not slow disease progression. But its biomarker findings are more complicated, revealing a disconnect between cerebrospinal fluid p-tau-217 and tau PET. ...